source
- Takeda’s ADC arcotatug tavatecan shows survival benefit in phase 3 gastric cancer trialTakeda, together with Innovent Biologics, presented results from a late‑stage study of its next‑generation claudin‑18.2 antibody‑drug conjugate, arcotatug tavatecan (also known as IBI343 or TAK‑921…
- Tango Therapeutics reports 82% tumor response in combo trial for advanced pancreatic cancerTango Therapeutics and Revolution Medicines presented data showing that their experimental combination therapy produced tumor responses in 82% of patients with a specific form of advanced pancreati…